Akso Health Group
Akso Health Group HX Peers
See (HX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HX | $2.24 | -4.27% | 53.4M | -1.84 | -$1.22 | N/A |
| MCK | $719.68 | -1.17% | 90B | 27.99 | $25.71 | +0.40% |
| COR | $292.39 | -1.07% | 56.7B | 33.88 | $8.63 | +0.74% |
| CAH | $162.41 | +0.62% | 38.8B | 25.42 | $6.39 | +1.25% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $70.79 | +0.85% | 8.6B | 22.05 | $3.21 | N/A |
| PBH | $83.65 | -0.38% | 4.1B | 19.50 | $4.29 | N/A |
| PDCO | $31.33 | -0.90% | 2.8B | 20.48 | $1.53 | +1.66% |
| GRDN | $19.78 | +0.46% | 1.3B | -12.44 | -$1.59 | N/A |
| OMI | $7.93 | +1.73% | 607.2M | -1.66 | -$4.76 | N/A |
Stock Comparison
HX vs MCK Comparison
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, MCK has a market cap of 90B. Regarding current trading prices, HX is priced at $2.24, while MCK trades at $719.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas MCK's P/E ratio is 27.99. In terms of profitability, HX's ROE is -0.04%, compared to MCK's ROE of -1.33%. Regarding short-term risk, HX is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for HX.
HX vs COR Comparison
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, COR has a market cap of 56.7B. Regarding current trading prices, HX is priced at $2.24, while COR trades at $292.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas COR's P/E ratio is 33.88. In terms of profitability, HX's ROE is -0.04%, compared to COR's ROE of +2.41%. Regarding short-term risk, HX is more volatile compared to COR. This indicates potentially higher risk in terms of short-term price fluctuations for HX.
HX vs CAH Comparison
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, CAH has a market cap of 38.8B. Regarding current trading prices, HX is priced at $2.24, while CAH trades at $162.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas CAH's P/E ratio is 25.42. In terms of profitability, HX's ROE is -0.04%, compared to CAH's ROE of -0.50%. Regarding short-term risk, HX is more volatile compared to CAH. This indicates potentially higher risk in terms of short-term price fluctuations for HX.
HX vs ABC Comparison
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, HX is priced at $2.24, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas ABC's P/E ratio is 21.92. In terms of profitability, HX's ROE is -0.04%, compared to ABC's ROE of +2.52%. Regarding short-term risk, HX is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for HX.
HX vs HSIC Comparison
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, HSIC has a market cap of 8.6B. Regarding current trading prices, HX is priced at $2.24, while HSIC trades at $70.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas HSIC's P/E ratio is 22.05. In terms of profitability, HX's ROE is -0.04%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, HX is more volatile compared to HSIC. This indicates potentially higher risk in terms of short-term price fluctuations for HX.
HX vs PBH Comparison
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, PBH has a market cap of 4.1B. Regarding current trading prices, HX is priced at $2.24, while PBH trades at $83.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas PBH's P/E ratio is 19.50. In terms of profitability, HX's ROE is -0.04%, compared to PBH's ROE of +0.12%. Regarding short-term risk, HX is more volatile compared to PBH. This indicates potentially higher risk in terms of short-term price fluctuations for HX.
HX vs PDCO Comparison
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, HX is priced at $2.24, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas PDCO's P/E ratio is 20.48. In terms of profitability, HX's ROE is -0.04%, compared to PDCO's ROE of +0.14%. Regarding short-term risk, HX is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for HX.
HX vs GRDN Comparison
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, GRDN has a market cap of 1.3B. Regarding current trading prices, HX is priced at $2.24, while GRDN trades at $19.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas GRDN's P/E ratio is -12.44. In terms of profitability, HX's ROE is -0.04%, compared to GRDN's ROE of -0.74%. Regarding short-term risk, HX is more volatile compared to GRDN. This indicates potentially higher risk in terms of short-term price fluctuations for HX.
HX vs OMI Comparison
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, OMI has a market cap of 607.2M. Regarding current trading prices, HX is priced at $2.24, while OMI trades at $7.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas OMI's P/E ratio is -1.66. In terms of profitability, HX's ROE is -0.04%, compared to OMI's ROE of -0.51%. Regarding short-term risk, HX is more volatile compared to OMI. This indicates potentially higher risk in terms of short-term price fluctuations for HX.
HX vs WGRX Comparison
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, WGRX has a market cap of 99.2M. Regarding current trading prices, HX is priced at $2.24, while WGRX trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas WGRX's P/E ratio is -1.79. In terms of profitability, HX's ROE is -0.04%, compared to WGRX's ROE of -1.74%. Regarding short-term risk, HX is more volatile compared to WGRX. This indicates potentially higher risk in terms of short-term price fluctuations for HX.
HX vs ZYXI Comparison
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, ZYXI has a market cap of 71.7M. Regarding current trading prices, HX is priced at $2.24, while ZYXI trades at $2.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas ZYXI's P/E ratio is -9.87. In terms of profitability, HX's ROE is -0.04%, compared to ZYXI's ROE of -0.24%. Regarding short-term risk, HX is less volatile compared to ZYXI. This indicates potentially lower risk in terms of short-term price fluctuations for HX.
HX vs GEG Comparison
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, GEG has a market cap of 61.7M. Regarding current trading prices, HX is priced at $2.24, while GEG trades at $2.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas GEG's P/E ratio is -44.20. In terms of profitability, HX's ROE is -0.04%, compared to GEG's ROE of -0.02%. Regarding short-term risk, HX is more volatile compared to GEG. This indicates potentially higher risk in terms of short-term price fluctuations for HX.
HX vs RDGT Comparison
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, RDGT has a market cap of 6.7M. Regarding current trading prices, HX is priced at $2.24, while RDGT trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas RDGT's P/E ratio is -0.34. In terms of profitability, HX's ROE is -0.04%, compared to RDGT's ROE of -0.36%. Regarding short-term risk, HX is more volatile compared to RDGT. This indicates potentially higher risk in terms of short-term price fluctuations for HX.
HX vs CVET Comparison
HX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HX stands at 53.4M. In comparison, CVET has a market cap of 0. Regarding current trading prices, HX is priced at $2.24, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HX currently has a P/E ratio of -1.84, whereas CVET's P/E ratio is -69.97. In terms of profitability, HX's ROE is -0.04%, compared to CVET's ROE of -0.06%. Regarding short-term risk, HX is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for HX.